Recommendations for Hepatitis B Immunoglobulin and Antiviral Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation

Mesut AKARSU,Soner ONEM,İlker TURAN,Gupse ADALI,Meral AKDOĞAN KAYHAN,Murat AKYILDIZ,Murat ALADAĞ,Yasemin Hatice BALABAN,Nilay DANIŞ,Murat DAYANGAÇ,Genco GENÇDAL,Hale SÜMER,Elif SERTESEN,Merve GÜRAKAR,Muhsin Murat HARPUTLUOĞLU,Gökgan KABAÇAM,Sedat KARADEMİR,Murat KIYICI,RAMAZAN İDİLMAN,zeki karasu

Özet

The combination of hepatitis B immunoglobulin and potent nucleos(t)ide analogs after liver transplantation is considered as the standard of care for prophylaxis against hepatitis B virus recurrence. However, the recommended doses, route of administration, and duration of HBIG administration remain unclear. Moreover, hepatitis B immunoglobulin-free prophylaxis with potent nucleos(t)ide analogs has shown promising disease outcomes in preventing hepatitis B virus recurrence. The current recommendations, produced by the Turkish Association for the Study of the Liver, Acute Liver Failure and Liver Transplantation Special Interest Group, suggest a reduced need for hepatitis B immunoglobulin administration with effective long-term suppression of hepatitis B virus replication using potent nucleos(t) ide analogs after liver transplantation